SeaStar Medical Completes Enrollment of SCD 005 Trial to Evaluate Safety of SCD in AKI and/or ARDS Patients with COVID-19
SeaStar Medical recently completed enrollment of its SCD-005 clinical trial to demonstrate the safety of Selective Cytopheretic Device (SCD) in acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS) with COVID-19 infection. This...
Study Shows Critically Ill Children with AKI Requiring CKRT Benefiting from Selective Cytopheretic Device (SCD)
There are no definitive therapies for critically ill children who develop acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT). AKI independently multiplies short- and long-term mortality risk and approximately doubles...